Lysophosphatidic Acid Receptors 1 and 2 Play Roles in Regulation of Vascular Injury Responses but Not Blood Pressure by Panchatcharam, Manikandan et al.
Lysophosphatidic acid receptors 1 and 2 play roles in regulation
of vascular injury responses, but not blood pressure
Manikandan Panchatcharam1, Sumitra Miriyala1, Fanmuyi Yang1, Mauricio Rojas2,
Christopher End2, Christopher Vallant2, Anping Dong1, Kevin Lynch3, Jerold Chun4,
Andrew J. Morris1, and Susan S. Smyth1,2,5
1Division of Cardiovascular Medicine, The Gill Heart Institute, University of Kentucky, Lexington, KY 40536
2Carolina Cardiovascular Biology Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC
27599
3 Department of Pharmacology, University of Virginia, Charlottesville, VA
4Department of Molecular Biology, The Scripps Research Institute, San Diego, CA
5 Department of Veterans Affairs Medical Center, Lexington, Kentucky 40511
Abstract
Phenotypic modulation of vascular smooth muscle cells (SMC) is essential for the development of
intimal hyperplasia. Lysophosphatidic acid (LPA) is a serum component that can promote phenotypic
modulation of cultured SMC, but an endogenous role for this bioactive lipid as a regulator of SMC
function in vivo has not been established. Ligation injury of the carotid artery in mice increased levels
in the vessel of both autotaxin, the lysophospholipaseD enzyme responsible for generation of
extracellular LPA, and two LPA responsive G-protein coupled receptors 1 (LPA1) and 2 (LPA2).
LPA1-/-2-/- mice were partially protected from the development of injury-induced neointimal
hyperplasia, whereas LPA1-/- mice developed larger neointimal lesions after injury. Growth in serum,
LPA-induced ERK activation, and migration to LPA and serum were all attenuated in SMC isolated
from LPA1-/-2-/- mice. In contrast, LPA1-/- SMCs exhibited enhanced migration resulting from an
upregulation of LPA3. However, despite their involvement in intimal hyperplasia, neither LPA1 nor
LPA2 were required for dedifferentiation of SMC following vascular injury or dedifferentiation of
isolated SMC in response to LPA or serum in vitro. Similarly, neither LPA1 nor LPA2 were required
for LPA to elicit a transient increase in blood pressure following intravenous administration of LPA
to mice. These results identify a role for LPA and two defined LPA receptors in regulating SMC
migratory responses in the context of vascular injury, but suggest that additional LPA receptor
subtypes are required for other LPA-mediated effects in the vasculature.
Phenotypic modulation of vascular smooth muscle cells (SMCs) occurs in response to vascular
injury and is a critical component in the development of atherosclerotic and restenotic lesions
1, 2. Changes in the extracellular environment promote this response, which is characterized
by alterations in the differentiation state of SMCs and in their acquisition of the capacity to
proliferate and migrate. Isolated vascular SMCs from human and rodent species can be
stimulated to dedifferentiate, proliferate, and migrate by serum. The lipid mediator,
lysophosphatidic acid (LPA), has been proposed as one of the factors present in serum that
may promote phenotypic modulation of vascular SMCs 3-5.
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LPA, the simplest glycerophospholipid, promotes dedifferentiation3, proliferation 6-8, and
migration 9 of isolated vascular SMCs. Although the specific signaling systems involved in
SMC responses are not known, in other cell systems, LPA acts through at least five G-protein
coupled receptors, termed LPA 1 – 5, to stimulate a wide variety of intracellular signaling
pathways important in health and disease 10. Prominent among the pathways that are activated
by LPA include Rho GTPases and extracellular-signal regulated kinase (ERK), which are
known to play important roles in vascular SMC function. LPA has also been proposed to serve
as an endogenous activator of PPARγ 11, and there may be additional, yet-unidentified receptor
targets for LPA.
LPA is produced in locations that position it to be a pathophysiologic mediator of vascular cell
function. LPA is present in relatively low levels in plasma, but is more abundant in serum
where is it thought be derived at least in part through processes that require platelet activation
12-18. Therefore, local concentrations of LPA may be increased along vessels at sites of platelet
adhesion and thrombus formation. LPA is also found in abundance in the lipid-rich core of
atherosclerotic plaque, where is may be derived from mildly oxidized LDL19. Thus, LPA is
present, or can be formed, in the settings associated with alterations in SMC function. The
lysophospholipase D autotaxin (ATX), which catalyzes the hydrolysis of lysophospholipid
substrates, is responsible for generation of biologically active LPA in circulation. Mice that
are heterozygous for the wild type and null ATX allele have 50% normal circulating LPA levels
20, 21 and mice that transgenically overexpress ATX in the liver under control of the α-
antitrypsin promoter have elevated circulating levels of ATX and LPA 22.
Exogenous administration of LPA to animals elicits responses consistent with it serving as an
endogenous mediator of vascular cell function. For example, intravenous injection of LPA
elevates arterial blood pressure in rats 23 and local application causes cerebral vasoconstriction
in pigs 24. Moreover, local infusion of LPA in the rat common carotid artery induces vascular
remodeling by stimulating neointimal formation 25. A similar response is observed in mice
and may be mediated by PPARγ 26.
Until recently, a lack of appropriate and specific tools has limited our ability to define
pathophysiologic roles of endogenous LPA in the vasculature. In particular, the most extensive
in vitro studies reported to date have used rat or human SMC while responses of murine SMC
to LPA have not been examined in detail. A concerted analysis of murine SMC responses to
LPA in vitro coupled with a phenotypic analysis of vascular injury responses of LPA receptor
deficient mice is required to provide definitive insights into the role of LPA in this important
aspect of vascular function. In this report, we identify an upregulation of ATX and LPA
receptors 1 and 2 (LPA1 and LPA2) following vascular injury. We use mice deficient in LPA1
and 2 alone and in combination to define roles for these receptors and LPA in the
pathophysiologically relevant vascular responses and in the phenotypic modulation of SMCs
that occurs with vascular injury.
Methods
Mice
All procedures conformed to the recommendations of “Guide for the Care and Use of
Laboratory Animals” (Department of Health, Education, and Welfare publication number NIH
78-23, 1996) and were approved by the Institutional Animal Care and Use Committee. The
production and initial characterization of mice-deficient in LPA receptors 1 and 2 has
previously been described 27, 28. The mice were backcrossed for >10 generations to the BalbC
background. Mice were housed in cages with HEPA-filtered air in rooms on 12-h light cycles
and fed Purina 5058 rodent chow ad libitum. Systolic blood pressure and heart rate were
measured for five consecutive days in conscious mice using the Blood Pressure Analysis tail
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cuff system (Hateras Systems, Apex, NC) daily after training for one week. Mean intraartrial
pressure was measured by placement of a 1.4 Fr Millar catheter in the carotid artery of
isoflurane-anesthetized mice.
Vascular Injury
At various intervals after carotid surgery29, 30, 5 mm of aorta proximal to the suture were
removed and processed for RNA analysis by qualitative PCR (qPCR) or analysis of protein
markers by immunoblotting. Neointimal formation along the length of the vessel was assessed
at four weeks after surgery using computer assisted morphometry as has been previously
described 30. Digital images were taken with a high performance digital camera (resolution
3840 × 3072 pixels) attached to a Nikon 80i microscope with a 10× (NA = 0.3) or 20× (NA =
0.5) objective and analyzed with Metamorph software. Femoral artery denudation injury was
performed and analyzed at four weeks as previously described 31, 32.
Isolation of SMCs
Mouse aortic SMCs were obtained from thoracic aortas by removing the adventitia and
endothelium by digestion with collagenase type II (Worthington; 175 units/ml). The media
were further digested in solution containing collagenase type II (175 units/ml) and elastase
(Sigma; 0.5 mg/ml), which yielded ≈100,000 cells per aorta. Cells were grown in DMEM
containing 0.5 ng/ml EGF, 5 μg/ml insulin, 2 ng/ml bFGF, 10% FBS, 100 units/ml penicillin,
and 100 μg/ml streptomycin, and incubated at 37°C with 5% CO2/95% air. SMC lineage was
confirmed by the presence of immunoreactivity for α-actin (Sigma) in >99% of the cells.
Experiments involving SMCs were performed by using cells with a passage number ≤5.
Details of methods for SMC experiments can be found in Online Supplemental methods.
Statistical analysis
All results were expressed as mean ± standard error of the mean (SEM). In vitro studies were
repeated a minimum of three times and results analyzed by student t-test or ANOVA. Statistical
significance within strains was determined using ANOVA with multiple pair-wise
comparisons. Statistical analysis was performed using Sigma-STAT software, version 3.5
(Systat Software, Inc.). A p-value of less than 0.05 was considered significant.
Results
Exposure of isolated smooth muscle cells 3 or intact vessels 25 to exogenous LPA elicits SMC
phenotypic modulation; however the role of endogenous LPA in mediating SMC responses in
the context of vascular injury is not known. The aim of this study was to determine if LPA
contributes to vascular injury responses in intact organisms. To accomplish this aim, we used
mice deficient in candidate LPA receptors and pharmacological antagonists of these receptors
to attenuate normal LPA signaling in vascular SMC and determine the consequences on
vascular and isolated cells responses.
Upregulation of autotaxin (ATX) and LPA receptors following vascular injury
Following ligation injury, we observed a time-dependent increase in vessel-associated levels
of ATX protein that was ∼2.5 fold after 1 - 3 days (p<0.05 at 1 day and 3 days versus uninjured;
Figure 1A). ATX is a secreted lysophospholipase D responsible for generation of biologically-
active extracellular LPA. Increasing plasma levels of ATX elevates circulating LPA levels
22, therefore, extracellular LPA production along the vessel wall likely increases following
injury. In many systems, LPA elicits cellular effects via G-protein-coupled receptor signaling.
We therefore assessed the level of gene expression of the five known LPA receptors (LPA 1
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– 5) following injury and observed that expression of LPA1 and LPA2 increased following
carotid injury by 2.1 fold and 6.2 fold, respectively (Figure 1B).
LPA1-/-2-/- mice are partially protected from development of intimal hyperplasia in vascular
injury models while LPA1-/- mice exhibit positive remodeling characterized by an enhanced
neointimal response
Mice that are singly or doubly deficient in LPA1 and LPA2 (LPA1-/-, LPA2-/- and
LPA1-/-2-/- mice) are viable and fertile 27, 28, allowing us to use them to investigate a role for
these LPA signaling receptors in the regulation of vascular SMC responses. Carotid ligation
was performed in wild-type (WT) mice, LPA1-/-, LPA2-/- and LPA1-/-2-/- double knock-out
(DKO) mice. Four weeks after carotid ligation, neointima developed along the length of the
carotid in WT mice (Figure 2A and 2B). The extent of intimal area and the intima/media ratio
was similar in mice lacking LPA2 (Figure 2B and 2D). In contrast LPA1-/- mice displayed an
∼ 3-fold enhanced intimal area (Figure 2B), an increase in intima/media ratio (p <0.017 versus
WT; Figure 2D), a larger lumen area (Figure 2E), and a resulting increase in the area within
the external elastic lamina, consistent with positive remodeling (i.e maintenance of luminal
area) in the presence of heightened neointimal formation. Unlike either the LPA2-/- or
LPA1-/- mice which displayed normal and enhanced neointima, respectively, LPA1-/-2-/- DKO
were partially protected from the development of intimal hyperplasia with an ∼4-fold lower
intimal areas (p<0.05; Figure 2B) and intima/media ratios after carotid ligation (Figure 2D).
Medial areas were similar in all the mice (Figure 2C).
To determine if these results were model specific, we denuded the endothelium of the mouse
femoral artery to elicit the development of intimal hyperplasia and observed an enhanced injury
response that was broadly similar to that observed in the carotid artery ligation model in
LPA1-/- mice (see Online Figure 1). Additional experiments were not performed with the other
strains of LPA receptor deficient mice using this femoral artery model because of a high
incidence of acute arterial thrombosis in WT Balb/C.
Vascular injury elicits a characteristic sequence of events that includes inflammatory cell
recruitment and SMC dedifferentiation, proliferation, and migration. To investigate the
mechanism(s) by which LPA receptors might regulate vascular injury responses, we measured
markers for these events after ligation. Following injury, there was an increase in ERK
activation, as measured by the ratio of phosphoERK to total ERK, and the increase in ERK
activity returned to baseline by five days in LPA1-/-2-/- mice and by seven days in LPA1-/-
mice (Figure 3A). However, expression of the proliferation marker PCNA was upregulated to
similar extents in WT, LPA1-/-and LPA1-/-2-/- vessels (Figure 3B), suggesting that cell
proliferation following injury was similar in all genotypes. Likewise, lack of LPA1 and LPA2
did not affect SMC dedifferentiation following injury because down-regulation of SMC
markers occurred in all genotypes of mice examined (Figure 3B). Expression of IL-6 and the
neutrophil and monocyte derived- inflammatory marker myeloperoxidase (MPO) increased
following injury and was also unaffected by the absence of LPA1 and LPA2 (Figure 3C). As
detected by immunoblotting, vessel-associated CD68, MPO, and P-selectin, a marker of
platelet activation, increased following injury in all genotypes (see Online Figure 2). Taken
together, these results indicate that vascular inflammation, SMC dedifferentiation, and cell
proliferation are similar in WT, LPA1-/-and LPA1-/-2-/- arteries following injury. Since these
markers of proliferation and differentiation were unaltered by combined LPA1 and LPA2
deficiency we considered the possibility that the attenuation of injury induced intimal
hyperplasia in LPA1-/-2-/- mice involves a requirement for these receptors as regulators of SMC
migration which, as discussed below, we evaluated using primary cultures of mouse SMC.
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LPA1-/-2-/- vascular SMC exhibit attenuated proliferative responsiveness in vivo and in vitro
Although LPA responses of cultured SMCs from humans and rats have been investigated in
detail these types of studies have not been reported with mouse SMCs. To identify the
mechanistic basis for vascular injury response phenotypes observed in the LPA receptor
deficient mice, we examined proliferation, dedifferentiation, and migration responses to LPA
of isolated mouse vascular SMCs. No significant differences in growth of WT and LPA1-/-
SMC in serum were observed, but LPA1-/-2-/- SMC grew more slowly (Figure 4A). This
difference appeared to be dependent on the LPA component of serum because there was no
difference between PDGF-induced growth of wild type and LPA1-/-2-/- SMC (Figure 4B). LPA
regulates cell proliferation through ERK activation in many cell systems. Therefore, we
examined LPA-induced ERK responses in isolated SMC. LPA treatment of isolated SMC
increased ERK activation maximally at 5 – 10 min (Figure 4C). This response was
concentration-dependent with maximal activation observed with 1 μM LPA (data not shown).
A similar increase in LPA-induced ERK activity in SMCs cultured from LPA2-/- mice was
observed (data not shown). In contrast, there was an approximately two-fold reduction in the
initial burst of LPA-induced ERK activation in LPA1-/- SMC and a five-fold reduction in
LPA1-/-2-/- SMC (Figure 4C).
LPA1-/-2-/- SMCS exhibit decreased migration in response to LPA, while LPA1-/- SMCs exhibit
enhanced migration due to upregulation of the LPA3 receptor
Although the reduced proliferative responses observed in LPA1-/-2-/- SMC in vitro are
consistent with the protection of LPA1-/-2-/- mice from the formation of neointima in response
to injury, the lack of a change in proliferation markers following injury in LPA1-/-2-/- vessels
does not support the idea that protection from the development of intimal hyperplasia is a direct
result of attenuated cell proliferation. In many systems, LPA is a potent stimulus for migration,
therefore, we compared migration responses to LPA in SMC derived from wild type and LPA
receptor deficient mice (Figure 5). LPA, serum, and PDGF stimulated 4.7 ± 0.94, 6.44 ± .046,
and 11.5 ± 0.79 fold increases respectively in migration of SMC (Figure 5). The migration of
LPA1-/-2-/- cells was lower at baseline (0.39 ± 0.01 that of WT cells; p <0.01), and the cells
did not display any increase in migration to LPA and serum (Figure 5) although migration to
PDGF was preserved (10.5 ± 1.7 fold increase). In contrast, LPA1-/- cells were hypermigratory
at baseline (7.9 ± 1.8 fold higher than WT cells; p = 0.003) and displayed a further exaggerated
migration response to LPA and serum (Figure 5).
To determine if expression of an alternate LPA receptor might be responsible for the hyper-
migratory LPA response observed in the LPA1-/- cells, the assays were conducted in the
presence of VPC32301, a selective antagonist of the LPA3 receptor33. LPA3 antagonism had
a modest ∼30% inhibition of WT migration (22,978 ± 3507 versus 33,680 ± 6329 μm2 in
antagonist-treated and vehicle-treated cells, respectively), and inhibited LPA-induced ERK
activation in WT cells by 10 – 15%. LPA3 receptor antagonism reduced both baseline and
LPA-induced migration in LPA1-/- cells to levels observed in WT cells (Figure 5) and inhibited
LPA-induced ERK activation in LPA1-/- cells by ∼35%. We found that LPA3 receptor
expression was elevated 3.7 ± 0.2 fold in LPA1-/-, but not LPA2-/- or LPA1-/-2-/- cells as
compared to WT cells (see Online Table 1). To determine if upregulation of LPA3 expression
alone could account for the enhanced migration observed in LPA1-/- cells, LPA3 was
overexpressed in WT SMC using recombinant lentivirus vectors which resulted in enhanced
migration towards LPA and serum phenocopying the behavior of LPA1-/- cells (Figure 5).
LPA1 and LPA2 are not required for Rho activation or SMC dedifferentiation
Migration of SMC to LPA was attenuated by ERK and Rho kinase inhibitors (see Online Figure
3). Therefore, we examined LPA-induced Rho responses in WT, LPA1-/- and LPA1-/-2-/- SMC.
In two of three independent SMC cultures, LPA1-/- cells had higher active Rho at baseline, but
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no differences in LPA-induced Rho activation were observed in WT, LPA1-/- and
LPA1-/-2-/- SMC (Figure 6A). These results suggest that lack of ERK activation, rather than
changes Rho activation, account for the reduced migration in the LPA1-/-2-/- mice.
Both LPA and Rho have been implicated as regulators of the differentiation state of vascular
SMC 3. However, our results following carotid ligation suggest that neither LPA 1 nor LPA2
is required for injury-induced SMC dedifferentiation in vivo. To determine if either of these
receptors plays role in dedifferentiation of isolated SMC, we examined expression patterns of
the differentiation marker SMC myosin heavy chain. Expression of SMC myosin heavy chain
was high in confluent SMC deprived of serum for 72 hours (Figure 6B). Exposure of these
cells to 10% serum or 1μM LPA for twenty four hours down-regulated SMC myosin heavy
chain expression to a similar extent in WT, LPA1-/- and LPA1-/-2-/- cells (Figure 6B). Taken
together, these results suggest that LPA1 and LPA2 are not essential for LPA-triggered
dedifferentiation of SMC in vitro.
LPA1 and 2 do not mediate acute blood pressure responses to LPA or regulate systemic
blood pressure
The above results suggest that LPA regulates the vascular injury response by modulating
migratory properties of SMC. In other species, intravascular administration of LPA alters blood
pressure which likely results from direct effects on vascular smooth muscle cell contractility.
We sought to determine if the same receptors that regulate vascular SMC migration responses
to LPA also contribute to the effects of LPA on blood pressure. Intravenous infusion of BSA
conjugated-LPA transiently increased mean arterial blood pressure in anesthetized mice, with
10 pmoles of LPA being the lowest dose that reproducibly increased mean arterial blood
pressure above vehicle by 17 ± 6 mm Hg in WT mice. A similar response was observed in
mice lacking either LPA1 or LPA2 or both, suggesting that neither receptor is responsible for
acute increase in blood pressure elicited by LPA (Table 1). Likewise, there was no difference
in blood pressure or heart rate in conscious WT, LPA1-/-, LPA2-/- or LPA1-/-2-/- mice (Table
2).
Discussion
In this study, we provide the first demonstration for a role for the LPA signaling nexus in
endogenous regulation of pathophysiologic vascular responses. Specifically, we report that
mice deficient in two defined LPA receptors, LPA1 and LPA2, are protected from intimal
hyperplasia in response to vascular injury through a mechanism that can primarily be accounted
for by a decrease in the ability of LPA to promote migration of vascular SMC. Interestingly,
we also found that mice lacking LPA1 alone exhibited enhanced vascular injury responses
which correlated with an upregulation of a third LPA receptor, LPA3, and appear to result from
an enhanced LPA3-dependent vascular smooth muscle cell migratory response. These findings
suggest that LPA is a relevant regulator of the murine vascular injury response which focuses
attention on possible sources of LPA at sites of vascular injury. We found that injury elevated
vessel-associated levels of autotaxin, the lysophospholipase D responsible for generation of
extracellular LPA, This may reflect localized expression of autotaxin or, perhaps more likely,
recruitment of circulating autotaxin. Because autotaxin is responsible for generating circulating
LPA and the autotaxin substrate, lysophosphatidylcholine is abundant in the circulation, the
increase in vessel-associated autotaxin likely drives localized production of biologically active,
extracellular LPA at the site of injury, which in turn promotes SMC migration via LPA1 and
LPA2.
Comparison of the in vivo injury and in vitro SMC responses from mice that are singly or
doubly deficient in LPA1 and LPA2 identifies functional redundancy and cross-talk between
LPA receptors that has been reported in other cell types including cardiomyocytes and
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embryonic fibroblasts. For example, LPA-induced ERK activity is normal in LPA2-/- SMCs,
slightly reduced in LPA1-/- cells, and nearly completely attenuated in LPA1-/-2-/- SMC,
indicating that both LPA1 and LPA2 are required to produce maximal LPA activation of ERK
which likely accounts for the reduced proliferative responses in LPA1-/-2-/- cells in vitro.
LPA1-/-2-/- SMC display an attenuated migration response to LPA, which may also related to
the reduced ERK activity in response to LPA. These results also underscore the importance of
the LPA component to the pro-migratory effects of serum on these cells, because LPA1-/-2-/-
SMCs display reduced migration to both serum and LPA but not to PDGF.
Our results also point to LPA-dependent vascular signaling pathways that are not regulated by
LPA1 or LPA2. Specifically, SMC lacking both receptors appear to undergo essentially normal
dedifferentiation in response to serum, LPA, or vascular injury. Because of the possibility that
localized production of LPA could promote vasoconstriction at sites of vascular injury we were
particularly interested in evaluating the possible roles of LPA1 and LPA2 in blood pressure
regulation. However, although these receptors are clearly expressed and functional in vascular
SMC, we found that both systemic blood pressure and the acute, transient increase in arterial
blood pressure provoked by direct administration of exogenous of LPA was unaltered in
LPA1-/-, LPA2-/-, and LPA1-/-2-/- mice.
LPA exerts a range of effects in the cardiovasculature that include modulation of platelet
activation, recruitment and activation of inflammatory cells and regulation of blood pressure
that likely results from the ability of LPA to promote SMC contractility. Clearly much more
work will be required to associate these signaling functions of LPA with the identified LPA
receptors. One particularly interesting possibility is that the nuclear receptor PPARγ may
mediate some G-protein coupled receptor independent signaling actions of LPA11 and we note
that exogenously administered LPA may elicit neointimal formation in rodent vessels in a
PPARγ-dependent manner 26.
Emerging evidence supports a role for LPA in regulation of vascular development and function.
Mice lacking the LPA synthetic enzyme autotaxin/lysophospholipase D (Enpp2-/-) die
embryonically with defects in vascular development 20, 21 and homozygous inactivation of
the LPP3 gene which encodes a phosphatase enzyme responsible for inactivation of LPA also
results in early embryonic lethality resulting from defects in vascular development and
patterning. Our data add to the weight of the evidence that the LPA signaling axis may be
important in the regulation of pathophysiologically important vascular cells responses in adult
animals. Taken together, our results suggest that interference with the enzymes and receptors
responsible for LPA production and signaling would be a viable strategy for pharmacological
intervention in the process of intimal hyperplasia.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Increases in autotaxin/lysophospholipase D and LPA receptor expression following
arterial injury
Carotid arteries were isolated from control, uninjured mice or animals that underwent carotid
ligation. Autotaxin (ATX) expression was determined by immunoblotting and was
significantly higher (p<0.05 by ANOVA) at one and three days after injury n comparison to
uninjured control levels (A). LPA receptor expression was determined by quantitative PCR
(B). Results are expressed relative to uninjured vessel and presented as mean ± sd from 3
separate experiments.
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Figure 2. Alterations in the development of intimal hyperplasia in mice lacking LPA receptors
Representative CME-stained sections of carotid arteries at four weeks after surgery taken
approx 1.2 mm from the site of ligation in WT, LPA1-/-, LPA1-/-2-/- mice (A). Intimal area
(B), medial area (C), and intima/media ratio (D) and luminal areas (E) in μm2 along the length
of vessels in WT (WT; n = 8), LPA1-/- (n = 6), LPA2-/- (n = 6), LPA1-/-2-/- (n = 6) mice. * =
p<0.05 in comparison to WT by ANOVA with multiple pairwise comparisons.
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Figure 3. LPA1 and LPA2 are not required for injury-induced alterations in proliferation,
differentiation or inflammation markers
Carotid injury increases ERK activity in vessels from WT, LPA1-/-, and LPA1-/-2-/- mice (A),
although responses in the LPA1-/-2-/- vessels return to baseline within 3 days. Injury
upregulates PCNA gene expression and down-regulates SMC differentiation markers in WT
(WT), LPA1-/-, and LPA1-/-2-/- vessels (B). Upregulation of myeloperoxidase (MPO) and IL-6
occurs following injury and is similar in WT, LPA1-/-, and LPA1-/-2-/- mice (C). Results are
presented as mean ± SD from 3 separate experiments in vessels harvested at five days after
injury.
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Figure 4. Growth and ERK activity is attenuated in LPA1-/-2-/- SMC
Growth curves for isolated SMC in serum (A) or in response to 20 ng/ml PDGF (B) were
generated by counting viable cells at the indicated time points. LPA (1 μM) induces ERK
activation in WT cells, as measured by phosphoERK/total ERK ratios. LPA-induced ERK
activation is attenuated in LPA1-/-2-/- SMC (C). Results are presented as mean ± SD from three
independent cultures of SMC of each genotype. * = p<0.05 in comparison to WT by ANOVA.
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Figure 5. LPA receptor deficiency alters SMC migratory responses
SMC were stained with Diff-Quik® on the undersurface of a membrane with a 5 μm pore
following migration to media containing vehicle in 0.5% FBS or 1 μM LPA (top). Cell
migration in WT, LPA2-/-, LPA1+/-2-/-, and LPA1-/-2-/- cells towards 1 μM LPA, 10% serum,
or 20 ng/ml PDGF (bottom left). Comparison of migratory responses of WT and LPA1-/- SMC
(bottom right). Enhanced migration in LPA1-/- SMC is attenuated by the LPA3 antagonist
VPC32301 (10 μM) and overexpression of LPA3 increases WT migration. Results from at
least three separate experiments are reported as mean ± SD of surface coverage by migrated
cells in μm2. nd = not determined.
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Figure 6. Neither LPA1 nor LPA2 are required for isolated SMC dedifferentiation
Expression of SMC-specific myosin heavy chain in cultured SMCs after serum deprivation,
or following re-exposure to either 10% FCS or 1 μM LPA for 24 hours (A). Rho activity was
examined 10 min after exposure of cells to LPA (1 μM) by Rhotekin pulldown assay (B).
Values represented results obtained from three separate experiments and are reported as a fold
change from baseline in WT cells (mean ± SD). S1P = sphingosine-1-phosphate.
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Table 1
Blood pressure and heart rate in WT mice and mice lacking LPA1 and/or LPA2
Genotype n Systolic BP* Heart Rate§
WT 6 124 ± 26 621 ± 38
LPA1-/- 9 126 ± 12 621 ± 46
LPA2-/- 12 133 ± 11 623 ± 46
LPA1-/-2-/- 4 120 ± 24 588 ± 66
*
Values are presented as mean ± SD in mmHg for systolic blood pressure or
§
beats per minute for heart rate. There is not a statistically significant difference in blood pressure (p = 0.500) or heart rate (p = 0.621).
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Table 2
Increase in mean arterial pressure in response to intravenous administration of LPA
Genotype n Change in MAP* Weight (gms)
WT 5 17 ± 6 29 ± 4
LPA1-/- 3 25 ± 8 22 ± 4
LPA2-/- 3 19 ± 8 23 ± 1
LPA1-/-2-/- 2 20 ± 2 29 ± 4
*
Values are presented as mean ± SD in mmHg. No statisticially significant difference between groups was observed (p = 0.466).
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